Harrison.ai vs Owkin

Owkin has a disclosed valuation of $1B, while Harrison.ai's valuation is not publicly available, making a direct size comparison difficult. Owkin employs 450 people.

Owkin has raised more in total funding at $334M, compared to Harrison.ai's $129M — a gap of $205M. Combined, the two companies have completed 3 known funding rounds.

Owkin holds the higher Awaira Score at 69/100, compared to Harrison.ai's 68/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 1-point gap that reflects meaningful differences in scale or traction.

Harrison.ai was founded by Aengus Tran in 2018. Owkin was founded by Thomas Clozel in 2016. Visit each company's profile on Awaira for a full founder biography.

Harrison.ai: Harrison.ai develops AI radiology and pathology analysis software for clinical deployment, building FDA-cleared and TGA-registered algorithms for chest X-ray abnormality detection, CT pulmonary angiography analysis, and mammography screening under its Annalise.ai product brand. The Sydney company focuses on AI clinical decision support that helps radiologists prioritise worklists, detect abnormalities, and reduce reporting errors in high-volume radiology departments.\n\nThe company raised approximately $129 million including a Series C from investors including Blackbird Ventures, Skip Capital, and Telstra Ventures. Harrison.ai has deployed its Annalise.ai platform across Australian hospital networks and has received US FDA clearance for its chest X-ray AI product, enabling international commercial expansion beyond Australia. The company has published clinical validation studies demonstrating AI performance that is non-inferior to specialist radiologist reads on chest X-ray abnormality detection across multiple institutions.\n\nHarrison.ai competes in the AI radiology market against Aidoc, Lunit, Qure.ai, and Behold.ai, which all target radiologist workflow assistance and clinical alerting. The Australian healthcare market provides a strong home base given the National Health Service framework and centrally coordinated radiology procurement, while FDA clearance opens the substantially larger US radiology AI market. The company is considered one of Australia most promising medical AI companies and a flagship for the Australian healthcare technology ecosystem. Owkin: Owkin is a French AI healthcare company founded in 2016 that develops federated learning and privacy-preserving machine learning technologies for drug discovery and clinical research. The company operates a distributed AI platform enabling pharmaceutical companies, biotech firms, and research institutions to collaborate on data analysis without sharing sensitive patient information or proprietary datasets. Owkin's core technology utilizes federated learning, allowing multiple parties to train machine learning models collectively while maintaining data privacy and regulatory compliance, particularly under GDPR and HIPAA frameworks. The company has raised $334 million in total funding and achieved a $1.0 billion valuation, positioning it as a significant player in the intersection of AI, privacy-tech, and healthcare. Owkin operates in the Series B stage and serves pharmaceutical companies seeking to accelerate drug development through collaborative AI while preserving data confidentiality. The platform addresses a critical challenge in healthcare AI: enabling large-scale machine learning without centralizing sensitive medical data. Owkin's approach contrasts with traditional cloud-based analytics solutions by maintaining data sovereignty at source institutions. The company has established partnerships across the pharmaceutical and research sectors, though specific customer names and financial metrics remain Not disclosed. Its growth trajectory reflects expanding demand for privacy-preserving AI solutions in highly regulated healthcare markets. Owkin combines federated learning with healthcare applications, enabling collaborative AI research without compromising data privacy or regulatory compliance across distributed pharmaceutical ecosystems.

Owkin was founded first in 2016, giving it 2 years of additional market experience. Harrison.ai was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Harrison.ai has approximately 100-500 employees, while Owkin has approximately 450. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Harrison.ai and Owkin are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.